person · Reporting owner
TomEnterprise Private AB
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | 10% owner | July 23, 2025 | July 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date July 23, 2025 · Filed July 25, 2025
Jointly reported with Von Koch Thomas, TomEnterprise AB
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote 1 | 8,383,577 |
Reported balance
After 2025-07-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-07-23 · Purchase · Acquired 2,857,142 · Balance 8,383,577 F1: These shares are owned directly by TomEnterprise Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are owned directly by TomEnterprise Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2025 Filed Jul 25, 2025 21:49 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseCommon Shares | 2,857,142 | $3.50 | $9,999,997.00 |
DisclosureSEC source: 0001104659-25-070900 · tm2521564-2_4seq1.xml · nonDerivative · entry 1 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEnterprise Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 8,383,577 F1 · ownership.nature: These shares are owned directly by TomEnterprise Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 20:27 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseCommon Shares | 1,200,000 | $2.50 | $3,000,000.00 |
DisclosureSEC source: 0001104659-24-076844 · tm2418593-2_4seq1.xml · nonDerivative · entry 1 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEnterprise Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 5,526,435 F1 · ownership.nature: These shares are owned directly by TomEnterprise Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 20:11 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseCommon Shares | 1,470,588 | $3.40 | $4,999,999.20 |
DisclosureSEC source: 0001104659-23-075250 · tm2319568-2_4seq1.xml · nonDerivative · entry 1 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEqt Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 4,326,435 F1 · ownership.nature: These shares are owned directly by TomEqt Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 20:19 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | PurchaseCommon Shares | 2,855,847 | $1.24 | $3,526,971.05 |
DisclosureSEC source: 0001567619-22-021344 · doc1.xml · nonDerivative · entry 2 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEqt Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 2 Disclosed balance after: 2,855,847 F2 · ownership.nature: These shares are owned directly by TomEqt Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEqt Private AB. Thomas Von Koch has the sole power to vote and dispose of these shares. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 20:19 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | SaleCommon Shares | 2,855,847 | $1.24 | $3,526,971.05 |
DisclosureSEC source: 0001567619-22-021344 · doc1.xml · nonDerivative · entry 1 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEqt Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 1 Disclosed balance after: 0 F1 · ownership.nature: These shares were owned directly by TomEnterprise AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.